Obtaining Patents Clause Samples

POPULAR SAMPLE Copied 1 times
Obtaining Patents. STANDARD shall have sole discretion to decide whether to obtain any patent or other protection on any Invention. If STANDARD seeks any such protection, the Executive shall have no obligation to pay any expenses of the filing or maintenance of any such patent or other protection.
View SourceView Similar (5)
Obtaining Patents. CALIBRE or the Company shall have sole discretion to decide whether to obtain any patent or other protection on any Invention. If CALIBRE or the Company seeks any such protection, the Executive shall have no obligation to pay any expenses of the filing or maintenance of any such patent or other protection.
View SourceView Similar (8)
Obtaining Patents. PSI or the Company shall have sole discretion to decide whether to obtain any patent or other protection on any Invention. If PSI or the Company seeks any such protection, the Executive shall have no obligation to pay any expenses of the filing or maintenance of any such patent or other protection.
View SourceView Similar (2)
Obtaining Patents. The Sellers agree that they will use their best efforts in cooperation with, and at the request of, Milestone to obtain United States and worldwide patent rights to the Intellectual Property and any improvements thereon or thereto, which together with all patents and patent applications are collectively referred to as the “Proprietary Rights”. The expense for preparing and filing appropriate patent applications and if commercially reasonable, obtaining foreign patents in such jurisdiction as appropriate, shall be borne by Milestone. Sellers shall assign all rights in and to all patent applications, patents and other Proprietary Rights not previously assigned or developed after the date hereof to Milestone.
View SourceView Similar (2)
Obtaining Patents. MP (on its own behalf and that of its ------------------ Affiliates) agrees, at its own expense, to file and prosecute diligently patent applications covering the Licensed Products in the countries of the United States, the European Patent Office, Japan and Canada (known as Group "A" countries) or other countries as it may be requested to do so by IGEN (known as Group "B" countries), and to maintain where required, by payment of renewal fees or taxes, any patents issued thereon. MP shall be responsible for all patent expenses relating to the Group "A" countries unless it decides to abandon such patent or application and IGEN shall be responsible for the reasonable pro rata expenses in the Group "B" countries, said pro rata expenses to be shared equally on a country-by-country basis by all licensees of MP who request coverage in that country. If MP decides to abandon an application or patent, MP will inform IGEN of its intent to abandon such patent or application in sufficient time that IGEN may assume prosecution and/or ownership at its own expense and no further royalties under that patent or application shall be due. MP shall keep IGEN or its counsel informed of all developments in connection with each filing and prosecution, promptly furnishing to IGEN or its counsel copies of all applications, official actions, amendments, issued patents and all other papers filed or received. All patents obtained pursuant to this Section 5.2 shall become a part of the Licensed Patent Rights.
View Source
Obtaining Patents. Sangamo shall, at its expense, use commercially reasonable efforts to obtain patent protection covering (a) the ZFN Reagents (other than Improved ZFN Reagents); (b) the use of such ZFN Reagents in CHO cell lines to create ZFN Modified Cell Lines; and (c) ZFN Modified Cell Lines. Sangamo may, at its sole discretion, use the Research Results to fulfill its obligations under the preceding sentence. Further, in consultation with Genentech, Sangamo shall, at its expense, use commercially reasonable efforts to file a patent application that specifically claims [***]. Sangamo shall assign any such application to Genentech, and Genentech shall control prosecution of such application.
View Source

Related to Obtaining Patents

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Patents and Patent Applications To the Company’s knowledge, all patents and patent applications owned by or licensed to the Company or under which the Company has rights have been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which could reasonably be expected to preclude the grant of a patent in connection with any such application or could reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.

  • INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS A. General 1. NASA has determined that 51 U.S.C. § 20135(b) does not apply to this Agreement. Therefore, title to inventions made (conceived or first actually reduced to practice) under this Agreement remain with the respective inventing party(ies). No invention or patent rights are exchanged or granted under this Agreement, except as provided herein.

  • Licensed Patent Rights The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of: